Adma Biologics (ADMA) Current Assets (2011 - 2025)

Adma Biologics' Current Assets history runs 14 years deep, the most recent figure standing at $466.5 million for Q4 2025.

• Quarterly Current Assets rose 40.77% year-over-year to $466.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $466.5 million (up 40.77% YoY) and the FY2025 annual result came in at $466.5 million, up 40.77% from the prior year.
• Current Assets was $466.5 million for Q4 2025 at Adma Biologics, up from $402.7 million in the prior quarter.
• Across five years, Current Assets topped out at $466.5 million in Q4 2025 and bottomed at $171.4 million in Q2 2021.
• A 5-year average of $280.0 million and a median of $268.3 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets dropped 4.95% — and 2025, when it soared 40.77%.
• Adma Biologics' Current Assets stood at $208.7 million in 2021, then advanced by 29.55% to $270.4 million in 2022, then fell by 4.95% to $257.0 million in 2023, then increased by 28.95% to $331.4 million in 2024, then surged by 40.77% to $466.5 million in 2025.
• Business Quant data shows ADMA's Current Assets at $466.5 million in Q4 2025, $402.7 million in Q3 2025, and $399.6 million in Q2 2025.